AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Abbvie (ABBV) PT Raised to $154 at BMO Capital
February 3, 2022 7:19 AM ESTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $154.00 (from $153.00) while maintaining an Outperform rating.
The analyst commented, "4Q good overall despite slight revenue shortfall as many key growth drivers performed well and better op. leverage drove EPS... More
AbbVie (ABBV) Tops Q4 EPS by 3c, Offers Guidance
February 2, 2022 7:44 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $3.31, $0.03 better than the analyst estimate of $3.28. Revenue for the quarter came in at $14.89 billion versus the consensus estimate of $14.95 billion.
GUIDANCE:
AbbVie sees FY2022 EPS of $14.00-$14.20, versus the consensus of... More
